Par Drugs And Chemicals Limited · NSE:PAR
Par Drugs And Chemicals — Investor Presentation (November 2019)
28 slides from Par Drugs And Chemicals's investor presentation, Nov 12, 2019
Slide 1: Cover letter to National Stock Exchange
Registered Office : 805, Dwarkesh Complex, R. C. Dutt Road, Alkapuri, re | Vadodara - 390 007. Gujarat (INDIA). | Ph. : +91-265-2342018 / 2332018 | Fax: +91-265-2332018 Corporate Office : 302, Anmol Plaza, Waghawadi Road, Bhavnagar. | Ph. : +91-278-2447013 DRUGS AND CHEMICALS LIMITED Email : admin@p
Slide 2: Investor Presentation | November 2019
Investor Presentation| November 2019
Slide 3: Executive Summary
2 Executive Summary Overview • Incorporated in 1999, Par Drugs and Chemicals Ltd. (PDCL) is engaged in the development and manufacture of Active Pharma Ingredients (“APIs”) and Fine Chemicals for the domestic market as well as for exports to international markets. • The company currently produces th
Slide 4: Company Overview
Company Overview
Slide 5: About the Company
4 About the Company Operational Revenues (INR Mn) • Promoted by Mr. Falgun Savani and Mr. Jignesh Savini, Par Drugs and Chemicals Ltd. (PDCL) was founded in 1982 and is engaged in the development and 199 134 164 manufacturing of APIs. 97 • The Company today manufacturers more than 23 different produ
Slide 6: Board of Directors
5 Board of Directors Falgun Vallabhbhai Savani Pravin Manjibhai Bhayani Managing Director Independent Director • Holds Bachelor’s degree in Pharmacy from B. K. Modi Government Pharmacy Collage, Rajkot affiliated with Saurashtra University. • Has 18 years of experience in API Industry and is playing
Slide 7: Geographical Presence
6 Geographical Presence Canada United Kingdom Germany Iran Hong Kong Japan India Bangladesh UAE Thailand Colombia 40+ 13+ Manufacturing Facility Bhavnagar, Gujarat having a capacity of 8,300 MTPA. Agents Globally Dealers in India
Slide 8: Key Milestones
7 Key Milestones Mr. V. J. Savani established in the year 1982 in the name of Par Inorganics, later Par Drugs and Chemicals was incorporated in the year 1999. • Established 2nd manufacturing facility in Asia's Received GMP • Had addition of one • Conversion from biggest chemicals Certification from
Slide 9: Research & Development
8 Research & Development • Company’s focus is on developing non-infringing processes and achieving process improvements and production cost efficiencies. • The main focus will be to expand the ability to penetrate different applications of current molecules with modified physical and chemical struct
Slide 10: Manufacturing Facility
9 Manufacturing Facility Manufacturing Facility - Chitra, Bhavnagar, Gujarat There are three Manufacturing Blocks are for different products having a capacity of 8,300 MTPA. Unit 1 – APIs Unit 2 - Magnesium Hydroxide Unit 3 - Fine Chemicals
Slide 11: Manufacturing Process
10 Manufacturing Process Procurement of Raw Quality Control and Reaction Filtration Drying Packaging Material Sampling Procurement of Chemical reaction After the reaction, Excess water from The sampling is The material is sent magnesium takes place in a the slurry has to be the product is done for t
Slide 12: Key Strengths
11 Key Strengths Diversified Portfolio: The company manufactures the entire range of products in the Antacid segment. Product portfolio presently comprises 16 APIs and 7 Fine Chemicals which are marketed domestically and exported. Global Presence: The Company is operating both in domestic and export
Slide 13: Business Overview
Business Overview
Slide 14: Business Overview
13 Business Overview The company is one of the largest manufacturer in Magnesium Hydroxide, Sucralfate and Magnesium Trisilate in India. API (67%) Fine Chemicals (33%) Magnesium Hydroxide Magnesium Oxide USP Precipitated Silica Sucralfate Almagate BP Allusil Dried Aluminium Hydroxide Gel Magnesium C
Slide 15: Business Verticals
14 Business Verticals API • PDCL currently produces the entire range of Antacid Molecules available in the market. • Antacids are medication that neutralize stomach acid to cut down on heartburn, sour stomach, acid indigestion, and stomach upset, symptoms of Gastroesophageal Reflux Disease (GERD als
Slide 16: APIs and their Applications
15 APIs and their Applications Magnesium Hydroxide Amorphous Aluminium Hydroxide Dried Magnesium Aluminium Silicate • Widely used as an Antacid in many Formulations • Mainly used as an active medicament in an • Used as an Antacid Raw material in a specific helping reduce stomach acid Antacid Formula
Slide 17: Fine Chemicals and their Applications
16 Fine Chemicals and their Applications Fine chemicals are chemical substances prepared to a very high degree of purity. They can be used in different industries. These chemicals are used for special applications by manufacturing firms that make the following products: Pharmaceuticals, paints, petr
Slide 18: Future Strategy
17 Future Strategy Expand the product portfolio: Seek to leverage the R&D capabilities to expand PDCL’s Product Portfolio and thus penetrate the different segments of application and value added products. This will ultimately increase the profitability by value addition. Exploring new geographical a
Slide 19: Industrial Overview
Industrial Overview
Slide 20: API Industry
19 API Industry Global API Market Size Global Anatcid Market Size (USD Bn) (USD Bn) • More than 30% of the APIs manufactured in India are exported to countries such as US, UK, CAGR 6.5% CAGR 3.7% Japan, etc. The total production market of API in India was valued at approximately USD 11 Bn in FY16. T
Slide 21: Fine Chemical Industry
20 Fine Chemical Industry • The global Fine Chemicals market is valued at USD 1,55,550 Mn in 2018 and is expected to reach USD 2,19,490 Mn by the end of 2024, growing at a CAGR of 7.1% between 2019 and 2024. • North America and Europe is the industry’s leading region. In 2018, the revenue of Fine Ch
Slide 22: Financial Overview
Financial Overview
Slide 23: Income Statement (IND-AS)
22 Income Statement (IND-AS) Income Statement (INR Mn) FY17 FY18 FY19 H1-FY20 Income from Operations 488 424 463 291 Total Expenses 403 344 381 239 EBITDA 85 80 82 52 EBITDA Margin 17.42% 18.87% 17.71% 17.87% Finance Cost 25 23 20 4 Depreciation 28 31 30 27 Other Income - - 1 - Share in profit of jo
Slide 24: Balance Sheet (IND-AS)
23 Balance Sheet (IND-AS) EQUITIES & LIABILITIES (INR Mn) FY18 FY19 H1-FY20 ASSETS (INR Mn) FY18 FY19 H1-FY20 Shareholder Funds 210 290 392 Non Current Assets 398 371 347 (A) Equity Share Capital 85 45 62 (A) Fixed Assets (B) Reserves & Surplus 125 245 330 (i) Tangible Assets 390 363 338 (B) Non Cur
Slide 25: Financial Highlights
24 Financial Highlights Operational Revenue (INR Mn) EBITDA (INR Mn) & EBITDA Margins (%) PAT (INR Mn) & PAT Margins (%) 18.87% 5.40% 488 463 85 424 82 3.89% 80 3.54% 25 19 17.71% 15 17.42% FY17 FY18 FY19 FY17 FY18 FY19 FY17 FY18 FY19 RoCE & RoE Debt to Equity Ratio Net Worth (INR Mn) RoE (%) RoCE (
Slide 26: Market Data
25 Market Data Price Data (30th September, 2019) INR Shareholding Pattern as on 30th September, 2019 Face Value 10 Market Price 46.5 Public High/Low 56.0/41.0 27% Market Cap (Mn) 286.1 Promoters 73% Equity Shares Outstanding (Mn) 6.15 1 Year Avg Trading Volume (‘000) 28.4
Slide 27: Disclaimer
26 Disclaimer Par Drugs & Chemicals Ltd Disclaimer: The above Presentation with slides have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connect
Slide 28: Thank You
Thank You
Par Drugs and Chemicals — Investor Presentation (November 2019) on 6ix